BioCryst Pharmaceuticals, Inc
(NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an ora...

Website: http://www.biocryst.com

Founded: 1986

Full Time Employees: 140

Sector: Healthcare

Industry: Biotechnology

Pharmaceuticals

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-09-30	2001-06-30	2001-03-31	2000-09-30	2000-06-30	2000-03-31

revenues	117,070,500	159,395,000	163,353,000	145,534,000	131,534,000	117,085,000	109,332,000	92,761,000	93,401,000	86,742,000	82,491,000	68,778,000
expenses:
cost of product sales	9,522,000	2,187,000	2,798,000	4,568,000	6,094,000	3,211,000	1,699,000	1,265,000	1,557,000	1,099,000	894,000	931,000	1,006,250	3,543,000	246,000	236,000	1,702,750	591,000	297,000	5,923,000	379,250	1,517,000			349,750			1,399,000
research and development	40,867,000	44,603,000	43,386,000	37,270,000	49,441,000	41,081,000	37,623,000	46,493,000	70,052,000	46,879,000	51,247,000	48,388,000	73,207,000	52,740,000	61,990,000	65,360,000	63,529,000	49,971,000	52,873,000	42,435,000	35,354,000	30,245,000	27,498,000	29,867,000	26,774,000	25,120,000	27,681,000	27,493,000	23,431,000	22,006,000	21,010,000	18,441,000	16,924,000	17,509,000	15,759,000	16,770,000	12,158,000	14,105,000	14,166,000	20,579,000	19,047,000	20,067,000	16,524,000	17,120,000	8,321,500	13,036,000	11,067,000	9,183,000	15,614,000	7,977,000	11,728,000	7,411,000		12,072,000	12,777,000	15,441,000	15,211,000	14,772,000	13,975,000	12,932,000	23,622,014	19,197,000	14,737,000	24,917,000	31,618,442	18,181,000	11,213,000	11,289,000	22,059,634	15,996,000	13,373,000	21,898,000	29,113,996	29,730,000	19,013,000	16,195,000	11,199,372	16,650,000	11,190,000	8,043,000	6,040,377	7,164,000	5,263,000	5,175,000	4,700,112	4,838,000	4,348,000
selling, general and administrative	95,781,000	83,014,000	87,383,000	82,469,000	80,470,000	65,084,000	61,214,000	59,364,000	64,382,000	50,648,000	50,997,000	47,867,000	50,153,000	36,919,000	38,017,000	34,282,000	35,387,000	34,992,000	26,325,000	22,114,000	20,986,000	17,195,000	13,883,000	15,865,000	10,489,000	11,735,000															2,721,000	2,731,000
total operating expenses	146,170,000	129,804,000	133,567,000	124,307,000	136,042,000	109,393,000	100,571,000	107,249,000	136,071,000	98,663,000	103,194,000	97,193,000	125,856,000	93,272,000	100,254,000	99,880,000	99,335,000	85,578,000	79,541,000	70,436,000	56,421,000	48,966,000	41,381,000	45,801,000	39,834,000	36,873,000	36,366,000	35,217,000	27,991,000	29,947,000	30,745,000	26,190,000	21,751,000	22,109,000	18,615,000	20,122,000	17,171,000	17,004,000	16,917,000	23,868,000	21,796,000	24,149,000	20,500,000	21,256,000	9,694,250	14,848,000	13,085,000	10,844,000	16,901,000	9,314,000	12,963,000	8,870,000
income from operations	260,385,000	29,591,000	29,786,000	21,227,000	-4,508,000	7,692,000	8,761,000	-14,488,000	-42,670,000	-11,921,000	-20,703,000	-28,415,000	-46,311,000	-17,445,000	-34,722,000	-49,957,000	-52,177,000	-44,584,000	-29,582,000	-51,377,000	-52,405,000	-42,864,000	-38,510,000	-40,978,000	-109,000	-35,098,000	-34,918,000	-29,330,000	-25,262,000	-28,493,000	-18,251,000	-22,214,000	-17,861,000	-13,349,000	-15,516,000	-10,685,000	-8,188,000	-9,241,000	-12,130,000	-19,048,000	-17,194,000	-13,162,000	5,342,000	-14,430,000	-15,156,000	-11,610,000	-11,619,000	-7,386,000	-6,334,000	-6,925,000	-12,142,000	-5,316,000		-8,016,000	-10,176,000	-5,001,000	-11,042,000	-12,805,000	-14,243,000	-11,499,000	-10,307,718	-10,990,000	-10,330,000	-2,729,000	15,085,776	-10,697,000	-8,739,000	-9,387,000	9,804,508	-9,573,000	-13,380,000	-14,016,000	-3,428,057	-11,862,000	-7,582,000	-9,408,000	-10,737,809	-16,459,000	-11,016,000	-8,767,000	-7,487,833	-7,927,000	-5,932,000	-5,830,000
yoy	-5876.06%	284.70%	239.98%	-246.51%	-89.44%	-164.52%	-142.32%	-49.01%	-7.86%	-31.67%	-40.37%	-43.12%	-11.24%	-60.87%	17.38%	-2.76%	-0.44%	4.01%	-23.18%	25.38%	47977.98%	22.13%	10.29%	39.71%	-99.57%	23.18%	91.32%	32.03%	41.44%	113.45%	17.63%	107.90%	118.14%	44.45%	27.91%	-43.90%	-52.38%	-29.79%	-327.07%	32.00%	13.45%	13.37%	-145.98%	95.37%	139.28%	67.65%	-4.31%	38.94%		-13.61%	19.32%	6.30%		-37.40%	-28.55%	-56.51%	7.12%	16.52%	37.88%	321.36%	-168.33%	2.74%	18.21%	-70.93%	53.87%	11.74%	-34.69%	-33.03%	-386.01%	-19.30%	76.47%	48.98%	-68.07%	-27.93%	-31.17%	7.31%	43.40%	107.63%	85.70%	50.38%
qoq	779.95%	-0.65%	40.32%	-570.87%	-158.61%	-12.20%	-160.47%	-66.05%	257.94%	-42.42%	-27.14%	-38.64%	165.47%	-49.76%	-30.50%	-4.25%	17.03%	50.71%	-42.42%	-1.96%	22.26%	11.31%	-6.02%	37494.50%	-99.69%	0.52%	19.05%	16.10%	-11.34%	56.12%	-17.84%	24.37%	33.80%	-13.97%	45.21%	30.50%	-11.39%	-23.82%	-36.32%	10.78%	30.63%	-346.39%	-137.02%	-4.79%	30.54%	-0.08%	57.31%	16.61%	-8.53%	-42.97%	128.40%			-21.23%	103.48%	-54.71%	-13.77%	-10.10%	23.86%	11.56%	-6.21%	6.39%	278.53%	-118.09%	-241.03%	22.41%	-6.90%	-195.74%	-202.42%	-28.45%	-4.54%	308.86%	-71.10%	56.45%	-19.41%	-12.38%	-34.76%	49.41%	25.65%	17.08%	-5.54%	33.63%	1.75%
operating margin %	Infinity%	Infinity%	Infinity%	Infinity%	-Infinity%	Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-58.22%	-23.01%	-52.98%	-100.07%	-110.64%	-108.76%	-59.21%	-269.57%	-1304.91%	-702.46%	-1341.34%	-849.64%	-0.27%	-1977.35%	-2411.46%	-498.22%	-925.69%	-1959.63%	-146.08%	-558.70%	-459.15%	-152.39%	-500.68%	-113.22%	-91.15%	-119.04%	-253.39%	-395.19%	-373.62%	-119.80%	20.67%	-211.40%	-278.30%	-358.55%	-792.56%	-213.59%	-59.94%	-289.87%	-1478.93%	-149.58%	NaN%	-139.14%	-241.71%	-40.92%	-211.37%	-243.95%	-381.34%	-211.57%	-61.74%	-91.58%	-135.64%	-10.47%	Infinity%	-Infinity%	-Infinity%	-Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	0%	0%	0%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%
other income:
interest income	2,890,000	2,238,000	2,516,000	3,024,000	3,570,000	3,591,000	3,554,000	4,031,000
interest expense	-14,135,000	-19,661,000	-21,582,000	-23,494,000	-24,449,000	-24,828,000	-24,733,000	-24,506,000	-24,583,000	-27,345,000	-28,915,000	-27,396,000	-26,458,000	-24,775,000	-24,022,000	-23,837,000	-18,780,000	-14,115,000	-13,495,000	-12,904,000	-5,609,000	-2,927,000	-2,918,000	-3,047,000	-3,087,000	-3,044,000	-3,035,000	-2,726,000	-2,414,000	-2,346,000	-2,195,000	-2,221,000	-2,231,000	-2,140,000	-2,094,000	-2,100,000	-2,131,000	-1,465,000	-1,421,000	-1,470,000	-1,338,000	-1,241,000	-1,306,000	-1,315,000	-921,000	-1,217,000	-1,225,000	-1,242,000	-1,242,000	-1,191,000	-1,165,000	-1,180,000		-1,166,000	-1,160,000	-1,160,000	-1,160,000	-1,160,000	-1,166,000	-288,000
foreign currency gains	-6,750	35,000		1,000	-9,250	98,000	-84,000				301,000				132,000
loss on extinguishment of debt	-10,421,000	-2,740,000	-4,171,000						-7,254,750		-29,019,000
other income	9,423,000	2,667,000
total other expense	-12,368,000	-17,461,000	-23,300,000	-20,469,000
income before income taxes	248,017,000	12,130,000	6,486,000	758,000	-25,991,000	-13,447,000	-12,502,000	-35,014,000	-63,162,000	-35,819,000	-74,586,000	-52,662,000	-71,465,000	-40,998,000	-58,003,000	-73,917,000
income tax expense	2,172,000	-769,000	1,401,000	726,000	804,000	586,000	172,000	365,000	-1,431,000	330,000	740,000	671,000	76,000	1,522,000	856,000	279,000
net income	245,845,000	12,899,000	5,085,000	32,000	-26,795,000	-14,033,000	-12,674,000	-35,379,000	-61,731,000	-36,149,000	-75,326,000	-53,333,000	-71,541,000	-42,520,000	-58,859,000	-74,196,000	-17,779,000	-58,801,000	-43,198,000	-64,284,000	-60,493,000	-46,115,000	-38,607,000	-37,599,000	-2,622,000	-37,592,000	-37,629,000	-31,054,000	-27,432,000	-29,597,000	-18,446,000	-25,777,000	-19,543,000	-15,134,000	-16,886,000	-14,219,000	-4,503,000	-11,528,000	-16,281,000	-22,832,000	-18,135,000	-14,621,000	4,901,000	-15,164,000	-11,672,000	-8,731,000	-14,649,000	-10,137,000	-5,429,000	-8,001,000	-12,172,000	-4,506,000		-9,700,000	-12,276,000	-6,052,000	-13,192,000	-14,459,000	-16,271,000	-13,027,000	-10,201,183	-10,864,000	-10,193,000	-2,595,000	15,151,465	-10,627,000	-8,684,000	-9,292,000	10,070,430	-8,995,000	-12,709,000	-13,098,000	-2,283,524	-10,984,000	-6,963,000	-8,825,000	-10,049,853	-15,603,000	-10,083,000	-7,882,000	-7,160,768	-7,645,000	-5,648,000	-5,645,000	-5,289,121	-5,296,000	-5,057,000
yoy	-1017.50%	-191.92%	-140.12%	-100.09%	-56.59%	-61.18%	-83.17%	-33.66%	-13.71%	-14.98%	27.98%	-28.12%	302.39%	-27.69%	36.25%	15.42%	-70.61%	27.51%	11.89%	70.97%	2207.13%	22.67%	2.60%	21.08%	-90.44%	27.01%	104.00%	20.47%	40.37%	95.57%	9.24%	81.29%	334.00%	31.28%	3.72%	-37.72%	-75.17%	-21.15%	-432.20%	50.57%	55.37%	67.46%	-133.46%	49.59%	114.99%	9.12%	20.35%	124.97%		-17.52%	-0.85%	-25.55%		-32.91%	-24.55%	-53.54%	29.32%	33.09%	59.63%	402.00%	-167.33%	2.23%	17.38%	-72.07%	50.45%	18.14%	-31.67%	-29.06%	-541.00%	-18.11%	82.52%	48.42%	-77.28%	-29.60%	-30.94%	11.96%	40.35%	104.09%	78.52%	39.63%	35.39%	44.35%	11.69%
qoq	1805.92%	153.67%	15790.63%	-100.12%	90.94%	10.72%	-64.18%	-42.69%	70.77%	-52.01%	41.24%	-25.45%	68.25%	-27.76%	-20.67%	317.32%	-69.76%	36.12%	-32.80%	6.27%	31.18%	19.45%	2.68%	1333.98%	-93.03%	-0.10%	21.17%	13.20%	-7.31%	60.45%	-28.44%	31.90%	29.13%	-10.38%	18.76%	215.77%	-60.94%	-29.19%	-28.69%	25.90%	24.03%	-398.33%	-132.32%	29.92%	33.68%	-40.40%	44.51%	86.72%	-32.15%	-34.27%	170.13%			-20.98%	102.84%	-54.12%	-8.76%	-11.14%	24.90%	27.70%	-6.10%	6.58%	292.79%	-117.13%	-242.58%	22.37%	-6.54%	-192.27%	-211.96%	-29.22%	-2.97%	473.59%	-79.21%	57.75%	-21.10%	-12.19%	-35.59%	54.75%	27.92%	10.07%	-6.33%	35.36%	0.05%	6.73%	-0.13%	4.73%
net income margin %	Infinity%	Infinity%	Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-89.94%	-56.08%	-89.82%	-148.62%	-37.70%	-143.44%	-86.47%	-337.29%	-1506.30%	-755.74%	-1344.72%	-779.58%	-6.60%	-2117.86%	-2598.69%	-527.50%	-1005.20%	-2035.56%	-147.64%	-648.31%	-502.39%	-172.76%	-544.89%	-150.67%	-50.13%	-148.50%	-340.11%	-473.69%	-394.07%	-133.08%	18.97%	-222.15%	-214.32%	-269.64%	-999.25%	-293.15%	-51.38%	-334.91%	-1482.58%	-126.79%	NaN%	-168.37%	-291.59%	-49.52%	-252.53%	-275.46%	-435.64%	-239.69%	-61.11%	-90.53%	-133.84%	-9.95%	Infinity%	-Infinity%	-Infinity%	-Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	1597.44%	-1961.48%	-2330.41%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%
other comprehensive income:
foreign currency translation adjustment	-1,219,000	-523,000	702,000	366,000	-946,000	563,000	-140,000	-253,000	247,000	-185,000	59,000	59,000	13,000	695,000	104,000	78,000	75,000	28,000	-92,000	178,000
unrealized gain on available for sale investments	117,000	17,000			-426,000	1,173,000	-74,000	-313,000	290,000	295,000	46,000	500,000				-69,000	-12,000	-1,000	-3,000	1,000	-6,000	6,000		-25,000	-21,000	19,000	130,000	208,000	113,000	42,000	24,000	-233,000				9,000	-34,000	-24,000	-2,000	254,000	32,250	91,000	-102,000	140,000								-12,000
total other comprehensive income	-1,102,000	-506,000	514,000	211,000
net comprehensive income	244,743,000	12,393,000	5,599,000	243,000
net income per common share: basic	1,170	60	20
weighted-average shares of common stock outstanding: basic	209,893,000	210,176,000	209,519,000	208,882,000
net income per common share: diluted	1,130	60	20
weighted-average shares of common stock outstanding: diluted	218,581,000	219,885,000	219,886,000	215,261,000
foreign currency losses			-63,000					-51,000	-374,000	-737,000		-229,000	-1,400,000	-538,000		-177,000
unrealized loss on available for sale investments			-188,000	-155,000									111,000	-808,000	-275,000																		-1,250	-2,000	-12,000													-2,000
royalty					37,000	17,000	35,000	127,000	80,000	37,000	56,000	7,000	113,000	70,000	1,000	2,000	1,000	24,000	46,000	-36,000	48,000	9,000		69,000	244,000	18,000	26,000	87,000	70,000	18,000	243,000	140,000	129,000	115,000	22,000	294,000	155,000	143,000	27,000	77,000	21,000	5,000	442,000	60,000	487,750	5,000	5,000	73,000	17,000		4,000	77,000
net comprehensive loss					-28,167,000	-12,297,000	-12,888,000	-35,945,000																-37,624,000				-30,846,000
basic and diluted net loss per common share					-130	-70	-60	-170	-310	-190	-400	-280	-380	-230	-320	-400	-100	-330	-240	-360	-340	-260	-240	-240	20	-340	-340	-280	-250	-280	-190	-260	-200	-180	-210	-190	-60	-160		-310	-250	-200		-210	-130	-120	-230	-170	-90	-140	-230	-90					-290	-320	-360	-290	529.24	-240	-230	-60	749.65	-280	-230	-240	909.35	-240	-330	-340	859.11	-320	-240	-300	1,148.5	-530	-350	-270
weighted-average shares outstanding					206,696,000	206,905,000	206,425,000	206,064,000	192,198,000	189,644,000	189,118,000	188,509,000	185,908,000	186,180,000	185,605,000	184,898,000	179,117,000	179,106,000	178,127,000	177,343,000	167,267,000	176,521,000	161,569,000	154,156,000	115,600,000	110,416,000	110,338,000	110,167,000	103,185,000	105,410,000	98,787,000	98,592,000	84,451,000	83,570,000	80,418,000	75,167,000	73,699,000	73,734,000		73,601,000	72,901,000	73,262,000		72,341,000	66,773	71,801,000	63,647,000	59,589,000	55,216,000	57,124,000	53,468,000	51,073,000	49,474,000					45,178,000	45,111,000	44,987,000	44,564,177	44,884,000	44,517,000	43,925,000	38,925,525	38,460,000	38,232,000	38,204,000	38,062,131	38,095,000	38,117,000	38,059,000	32,770,923	34,277,000	29,420,000	29,274,000	29,147,397	29,222,000	29,184,000	28,938,000	25,721,031	26,209,000	26,149,000	23,620,000	21,165,311	21,706,000						17,642,746
interest and other income									4,465,000	4,184,000	3,750,000	3,378,000	2,704,000	1,760,000	609,000	54,000	14,000	9,000	13,000	26,000			2,758,000	6,446,000	388,000	402,000	547,000	596,000	686,000	611,000	493,000	462,000	478,000	225,000	203,000	109,000	98,000	109,000	147,000	439,000	168,000	134,000	116,000	117,000	12,500	14,000	19,000	17,000	21,000	18,000	21,000	33,000		54,000	57,000	71,000	84,000	92,000	136,000	102,000	106,535	126,000	137,000	134,000	65,689	70,000	55,000	95,000	265,922	578,000	671,000	918,000	1,144,533	878,000	619,000	583,000	687,956	856,000	933,000	885,000	327,065	282,000	284,000	185,000
comprehensive loss									-41,008,500	-36,039,000	-75,221,000	-52,774,000	-43,962,500	-42,633,000	-59,030,000	-74,187,000	-41,543,000	-58,774,000	-43,293,000	-64,105,000	-30,587,750	-46,109,000	-38,618,000		-26,479,500	-37,573,000	-37,499,000		-18,496,750	-29,555,000	-18,422,000	-26,010,000	-19,769,000	-15,136,000	-16,898,000	-14,210,000	-4,537,000	-11,552,000		-22,578,000	-18,340,000	-14,530,000		-15,024,000	-8,379,750	-8,732,000	-14,648,000	-10,139,000	-5,427,000	-8,005,000	-12,181,000	-4,518,000		-9,700,000	-12,285,000	-6,043,000
product sales													78,063,000	75,213,000	64,888,000	49,546,000	45,908,000	39,141,000	33,430,000	17,871,000	605,000	2,478,000		218,000	15,519,000	335,000		1,679,000						1,501,000							55,000	5,699,000		537,000																				325,000
royalty revenue													1,416,000	600,000	540,000	347,000	347,000	322,000	128,000	-897,000	1,138,000	254,000	44,000	1,945,000	2,777,000	508,000	696,000	2,322,000	1,775,000	523,000	142,000	3,661,000	3,291,000	442,000	489,000	6,321,000	3,662,000	3,501,000	629,000	1,890,000	610,000	126,000	132,000	1,518,000			125,000	1,821,000	520,000	8,000	110,000	1,924,000		2,848,000
milestone revenue																			15,000,000
collaborative and other research and development													66,000	14,000	104,000	30,000	903,000	1,531,000	1,401,000	2,085,000	2,273,000	3,370,000	2,827,000	2,660,000	21,429,000	932,000	752,000	1,886,000	954,000	931,000	12,352,000	315,000	599,000	6,817,000	2,610,000	3,116,000	3,052,000	4,262,000	4,158,000	2,930,000	3,937,000	5,162,000	25,710,000	4,771,000	1,552,750	3,233,000	1,341,000	1,637,000	10,047,000	2,381,000	711,000	1,630,000		2,913,000	4,210,000	12,221,000	5,224,000	5,249,000	3,735,000	5,435,000	17,405,336	12,000,000	7,616,000	25,035,000	31,972,811	10,548,000	4,787,000	4,359,000	34,240,369	8,894,000	2,659,000	10,768,000	28,171,901	20,463,000	13,444,000	9,159,000	2,091,936	1,790,000	1,558,000	771,000	20,867	32,000	58,000	41,000	177,901	116,000	43,000
total revenues													79,545,000	75,827,000	65,532,000	49,923,000	47,158,000	40,994,000	49,959,000	19,059,000	4,016,000	6,102,000	2,871,000	4,823,000	39,725,000	1,775,000	1,448,000	5,887,000	2,729,000	1,454,000	12,494,000	3,976,000	3,890,000	8,760,000	3,099,000	9,437,000	8,983,000	7,763,000	4,787,000	4,820,000	4,602,000	10,987,000	25,842,000	6,826,000	5,446,000	3,238,000	1,466,000	3,458,000	10,567,000	2,389,000	821,000	3,554,000		5,761,000	4,210,000	12,221,000	5,224,000	5,249,000	3,735,000	5,435,000	16,694,336	12,000,000	7,616,000	26,071,000																					-331,099	270,000	217,000
yoy													68.68%	84.97%	31.17%	161.94%	1074.25%	571.81%	1640.13%	295.17%	-89.89%	243.77%	98.27%	-18.07%	1355.66%	22.08%	-88.41%	48.06%	-29.85%	-83.40%	303.16%	-57.87%	-56.70%	12.84%	-35.26%	95.79%	95.20%	-29.34%	-81.48%	-29.39%	-15.50%	239.31%	1662.76%	97.40%	-48.46%	35.54%	78.56%	-2.70%		-58.53%	-80.50%	-70.92%		9.75%	12.72%	124.86%	-68.71%	-56.26%	-50.96%	-79.15%
qoq													4.90%	15.71%	31.27%	5.86%	15.04%	-17.94%	162.13%	374.58%	-34.19%	112.54%	-40.47%	-87.86%	2138.03%	22.58%	-75.40%	115.72%	87.69%	-88.36%	214.24%	2.21%	-55.59%	182.67%	-67.16%	5.05%	15.72%	62.17%	-0.68%	4.74%	-58.11%	-57.48%	278.58%	25.34%	68.19%	120.87%	-57.61%	-67.28%	342.32%	190.99%	-76.90%			36.84%	-65.55%	133.94%	-0.48%	40.54%	-31.28%	-67.44%	39.12%	57.56%	-70.79%																						-222.63%	24.42%
expenses
gain on foreign currency																	-68,500	-111,000	-134,000
loss on foreign currency																				-29,000
interest and other income and expense																					2,223,000	-312,000
gain on foreign currency derivative																					7,750	-12,000	63,000	-20,000	186,000	148,000	-223,000	406,000	83,500	631,000	1,507,000		71,000	130,000	521,000		5,718,000	-931,000	-2,877,000	-2,753,000	229,000	-352,000	749,000	464,000	183,000	4,082,000	-1,824,000	-1,526,000	2,126,000	97,000	1,114,000	1,957,000				38,000
unrealized (loss) gain on available for sale investments																							-11,000
general and administrative																											8,659,000	6,238,000	6,256,000	7,923,000	9,492,000	7,609,000	2,308,750	3,343,000	2,834,000	3,058,000	2,173,000	2,756,000	2,724,000	3,212,000			3,534,000	4,061,000	1,353,250	1,812,000	2,013,000	1,588,000	1,270,000	1,337,000	1,231,000	1,382,000		1,591,000	1,609,000	1,781,000	1,055,000	3,282,000	4,003,000	4,002,000	3,379,581	3,793,000	3,209,000	3,797,000	3,647,187	3,064,000	2,313,000	2,457,000	2,376,227	2,471,000	2,666,000	2,886,000	2,485,962	2,595,000	2,013,000	2,372,000	1,630,373	1,599,000	1,384,000	1,495,000	1,468,323	795,000	727,000	696,000	897,316	728,000	926,000
cost of products sold																																		1,142,000							7,000	1,346,000		15,000																	459			86,000
loss on foreign currency derivative																																-1,804,000				-1,543,000																		-572,000	-997,000		-1,074,000	-586,000	-998,000	-1,342,000
basic net income per common share																																							-220				70
diluted net income per common share																																							-220				60
weighted-average shares outstanding, basic																																							73,695,000				72,642,000
weighted-average shares outstanding, diluted																																							73,695,000				76,760,000
comprehensive income																																							-16,283,000				4,799,000
unrealized loss on investments																																													-500	-1,000			-6,250	-4,000	-9,000
unrealized gain on investments																																															1,000								-9,000	9,000
royalty expense																																																						114,000
total expenses																																																						13,777,000	14,386,000	17,222,000	13,241,000	18,054,000	17,978,000	16,934,000	27,002,054	22,990,000	17,946,000	28,800,000	39,809,543	21,245,000	13,526,000	13,746,000	24,435,861	18,467,000	16,039,000	24,784,000	31,599,958	32,325,000	21,026,000	18,567,000	12,829,745	18,249,000	12,574,000	9,538,000	7,508,700	7,959,000	5,990,000	5,871,000	5,605,767	5,566,000	5,274,000
royalties																																																													177,750			711,000
revenues:
amounts per common share:
basic and diluted net loss																																																																																	-187.5	-290	-220	-240
interest and other																																																																																					127,250	154,000	174,000
weighted average shares outstanding																																																																																							21,618,000

Balance Sheets:

Quarterly

Annual

Unit: USD	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2002-12-31

assets
current assets:
cash and cash equivalents	89,736,000	84,078,000	88,033,000	105,190,000	104,713,000	96,841,000	78,410,000	84,333,000	110,643,000	150,905,000	146,215,000	155,136,000	304,767,000	246,899,000	272,571,000	395,504,000	504,389,000	199,597,000	210,314,000	226,902,000	272,127,000	96,492,000	173,468,000	101,873,000	114,172,000	29,903,000	30,760,000	34,804,000	26,731,000	52,584,000	27,104,000	43,767,000	50,282,000	117,776,000	39,696,000	75,158,000	22,104,000	35,387,000	8,661,000	12,902,000	28,899,000	46,627,000	76,781,000	48,367,000	54,540,000	121,157,000	121,519,000	13,584,000	21,164,000	26,050,000	19,767,000	14,805,000	20,891,000	23,959,000	21,924,000	27,661,000	16,444,000	22,441,000	17,008,000	31,342,000	13,622,370	11,174,000	14,021,000	19,876,000	41,124,937	18,226,000	13,810,000	16,305,000	22,342,058	15,952,000	25,141,000	27,875,000	31,155,320	44,092,000	7,178,000	9,207,000	4,417,528	7,733,000	25,055,000	43,015,000	29,156,827	9,097,000	9,240,000	22,049,000	8,838,464	13,809,000	17,046,000	13,824,289
restricted cash	201,000	579,000	492,000	291,000	210,000	813,000	1,795,000	1,798,000	1,804,000	1,584,000	1,574,000	1,463,000	1,472,000	1,444,000	1,448,000	3,354,000	3,345,000	4,296,000	4,348,000	4,008,000	2,221,000	2,213,000	2,188,000	1,559,000	1,551,000	1,547,000	4,629,000	2,394,000	1,544,000	1,506,000	7,625,000	4,599,000	3,286,000	3,122,000	5,357,000	2,798,000	1,546,000	1,506,000	4,426,000	1,965,000	1,612,000	1,622,000	1,569,000	2,637,000	150,000	150,000	150,000	150,000	151,000	150,000	2,129,000	616,000	308,000	300,000	2,230,000	955,000	625,000	625,000	1,416,000	625,000	625,000	625,000	625,000	625,000	625,000
short-term investments	185,011,000	128,795,000	172,005,000	189,902,000	216,137,000
trade receivables	106,818,000	91,325,000	91,177,000	93,394,000	79,069,000	72,456,000	68,759,000	60,586,000	56,950,000	53,646,000	57,667,000	48,639,000	50,599,000	42,610,000	41,491,000	36,415,000	29,413,000	26,212,000	27,620,000	18,386,000
inventory	5,398,000	5,232,000	5,044,000	6,873,000	8,087,000	7,562,000	4,450,000	29,781,000	28,683,000	29,630,000	27,033,000	27,466,000	27,533,000	27,019,000	23,378,000	16,144,000	15,791,000				7,039,000					1,776,000	1,000,000	600,000	1,649,000	821,000	221,000	7,000			1,305,000	655,000	500,000	2,232,000	1,949,000	1,949,000	1,612,000		1,308,000	1,210,000	683,000												263,000
prepaid expenses and other current assets	17,182,000	16,502,000	12,541,000	14,327,000	13,752,000	16,281,000	16,426,000	18,381,000	19,542,000	20,016,000	14,112,000	15,157,000	12,586,000	11,070,000	11,053,000	12,333,000	9,986,000	8,975,000	5,560,000	5,908,000	5,528,000	5,241,000	3,016,000	5,249,000	4,422,000	3,447,000	2,341,000	2,087,000	2,390,000	2,445,000	1,729,000	2,397,000	1,381,000	1,421,000	1,524,000	1,721,000	1,438,000	2,007,000	1,674,000	3,221,000	4,870,000	4,970,000	5,449,000	4,322,000	6,172,000	4,546,000	5,020,000	835,000	1,725,000	1,656,000	1,179,000	1,781,000	1,097,000	826,000	344,000	407,000	378,000	795,000	260,000	676,000	1,004,430	1,187,000	1,421,000	1,275,000	1,055,712	3,201,000	6,744,000	692,000	1,136,842	2,331,000	2,369,000	3,131,000	1,879,463	2,101,000	2,287,000	1,865,000	3,775,975	1,705,000	4,504,000	2,727,000	839,662	644,000	739,000	671,000	699,284	571,000	541,000	482,620
total current assets	404,346,000	355,684,000	398,462,000	409,977,000	421,968,000	427,125,000	363,457,000	447,100,000	495,966,000	502,466,000	511,056,000	490,883,000	516,500,000	509,001,000	494,853,000	511,714,000	566,136,000	252,743,000	265,802,000	273,771,000	323,800,000	162,436,000	203,837,000	125,508,000	164,345,000	78,803,000	103,719,000	117,649,000	114,352,000	128,495,000	92,669,000	104,156,000	125,391,000	175,370,000	92,263,000	113,502,000	66,987,000	64,632,000	46,112,000	50,425,000	65,990,000	84,502,000	107,088,000	81,366,000	89,343,000	135,144,000	138,250,000	35,731,000	42,121,000	46,839,000	33,530,000	35,407,000	41,978,000	46,582,000	45,064,000	52,949,000	52,858,000	60,446,000	79,877,000	100,451,000	87,418,974	89,762,000	79,755,000	92,790,000	111,022,152	50,686,000	57,451,000	65,129,000	75,024,706	80,111,000	55,620,000	77,259,000	91,704,652	91,561,000	51,428,000	47,288,000	45,789,686	48,659,000	61,246,000	71,794,000	81,100,061	31,479,000	33,791,000	41,708,000	23,872,379	23,524,000	24,705,000	24,931,427
long-term inventory	23,990,000	23,390,000	22,205,000	25,097,000	23,187,000	21,633,000	24,525,000
property and equipment	8,783,000	8,396,000	8,457,000	7,593,000	7,777,000	7,421,000	7,663,000	7,831,000	7,910,000	8,999,000	8,438,000	8,376,000	8,617,000	8,464,000	8,702,000	8,799,000	8,714,000	7,829,000	7,669,000	7,035,000	7,113,000	7,142,000	7,149,000	7,270,000	7,347,000	7,452,000	7,551,000	7,644,000	9,135,000	9,236,000	9,390,000	9,395,000	9,546,000	9,613,000	9,602,000	9,753,000	9,922,000	10,095,000	10,112,000	8,362,000	5,149,000
long-term investments	61,164,000	39,669,000	10,101,000	20,548,000	20,323,000	19,426,000	64,317,000				3,445,000	3,432,000	18,077,000	34,332,000			6,829,000
right of use assets	10,203,000	10,840,000	11,546,000	11,982,000	12,008,000
other assets	5,672,000	4,387,000	3,592,000	4,850,000	5,157,000	15,649,000	12,457,000	12,961,000	13,084,000	11,459,000	6,946,000	7,046,000	6,806,000	6,797,000	6,983,000	7,207,000	6,472,000	5,191,000	3,813,000	3,625,000	3,802,000	3,646,000	3,720,000	3,811,000	3,590,000	4,245,000	4,333,000	5,390,000	978,000	1,420,000	841,000	222,000	2,027,000	1,955,000	1,871,000	2,271,000	3,813,000	2,190,000	1,610,000	2,714,000	5,468,000	5,239,000	5,699,000	6,495,000	6,031,000	1,277,000	2,700,000	4,495,000	3,620,000	5,075,000	5,695,000	6,074,000	8,694,000	9,114,000	8,704,000	7,734,000	7,433,000	7,157,000	6,695,000	5,930,000
total assets	514,158,000	446,424,000	457,188,000	480,047,000	490,420,000	491,254,000	472,419,000	467,892,000	516,960,000	522,924,000	529,885,000	509,737,000	550,000,000	558,594,000	510,538,000	527,720,000	588,151,000	265,763,000	277,284,000	284,431,000	334,715,000	176,226,000	214,706,000	136,589,000	175,282,000	90,500,000	116,344,000	142,338,000	146,841,000	168,308,000	136,644,000	155,372,000	178,259,000	191,492,000	113,509,000	129,513,000	89,847,000	91,502,000	82,217,000	102,881,000	124,555,000	138,956,000	150,181,000	129,867,000	136,874,000	137,125,000	141,975,000	43,387,000	48,866,000	53,205,000	39,916,000	46,899,000	57,439,000	64,094,000	76,236,000	80,085,000	82,208,000	92,511,000	108,412,000	122,766,000	109,447,235	111,354,000	116,103,000	124,655,000	142,190,106	60,588,000	64,694,000	72,602,000	84,691,677	99,351,000	107,649,000	129,144,000	142,716,839	141,154,000	78,426,000	67,916,000	68,485,421	80,198,000	91,879,000	102,224,000	99,248,394	38,153,000	43,425,000	49,489,000	32,468,571	37,885,000	41,765,000	41,300,388
liabilities and stockholders’ deficit
current liabilities:
accounts payable	15,826,000	5,567,000	8,589,000	10,049,000	11,644,000	13,482,000	7,786,000	11,910,000	20,893,000	10,567,000	13,889,000	6,254,000	14,356,000	8,622,000	12,024,000	13,881,000	27,808,000	19,693,000	10,087,000	13,529,000	18,713,000	11,616,000	9,354,000	10,061,000	13,988,000	10,084,000	8,298,000	6,935,000	7,769,000	7,911,000	4,122,000	3,588,000	6,337,000	4,603,000	1,844,000	5,433,000	4,269,000	2,760,000	5,051,000	7,691,000	9,307,000	3,782,000	3,822,000	5,307,000	2,849,000	2,266,000	2,360,000	1,352,000	4,174,000	1,241,000	989,000	1,073,000	3,974,000	2,293,000	3,328,000	2,062,000	2,497,000	3,583,000	5,012,000	6,254,000	8,200,822	3,261,000	1,438,000	6,352,000	18,069,767	3,200,000	2,793,000	4,185,000	5,265,947	3,239,000	9,317,000	14,763,000	19,771,375	16,383,000	10,578,000	8,209,000	5,886,967	7,974,000	5,206,000	6,867,000	8,812,985	2,231,000	1,208,000	1,672,000	1,970,443	2,024,000	849,000	256,038
accrued expenses	126,413,000	118,778,000	107,114,000	92,635,000	113,292,000	104,197,000	89,598,000	79,249,000	102,882,000	77,392,000	75,300,000	75,212,000	87,565,000	69,265,000	79,711,000	63,584,000	72,670,000	56,308,000	48,765,000	32,719,000	33,942,000	30,462,000	24,843,000	20,192,000	21,365,000	24,954,000	19,343,000	16,547,000	15,891,000	15,120,000	19,409,000	15,624,000	12,699,000	11,871,000	12,329,000	11,335,000	10,836,000	10,782,000	11,783,000	17,328,000	16,237,000	23,027,000	19,001,000	12,291,000	11,723,000	11,252,000	7,309,000	6,312,000	5,742,000	7,668,000	5,773,000	5,647,000	9,860,000	8,035,000	8,206,000	9,253,000	12,616,000	12,030,000	12,309,000	11,997,000	16,486,920	13,613,000	10,250,000	11,336,000	15,794,800	11,145,000	7,248,000	6,010,000	8,442,398	9,107,000	2,730,000	5,498,000	2,863,815	2,902,000	1,249,000	1,537,000	1,506,712	1,630,000	1,547,000	1,482,000	1,252,018	1,216,000	1,053,000	1,011,000	563,961	1,244,000	1,209,000	443,524
share-based liability	13,743,000
operating lease liabilities	317,000	348,000	392,000	1,071,000	937,000	1,049,000	1,026,000	1,098,000	1,058,000
finance lease liabilities	1,312,000	1,435,000	1,616,000	1,795,000	1,835,000	1,839,000	1,681,000	1,642,000	1,590,000
royalty financing obligations	38,455,000	37,686,000	35,741,000	34,305,000	32,676,000	33,000,000	28,974,000	26,022,000	23,565,000	535,186,000	526,121,000	514,411,000	501,655,000	489,781,000	477,666,000	464,225,000	449,375,000
total current liabilities	196,066,000	190,237,000	177,160,000	139,855,000	160,384,000	153,567,000	129,065,000	119,921,000	149,988,000	90,763,000	93,498,000	85,157,000	105,514,000	81,637,000	95,390,000	81,017,000	103,718,000	133,608,000	115,601,000	101,201,000	105,654,000	111,777,000	102,650,000	92,699,000	92,335,000	82,169,000	71,948,000	66,326,000	69,477,000	64,357,000	74,173,000	75,342,000	74,836,000	69,237,000	58,937,000	58,557,000	54,360,000	51,520,000	56,194,000	63,070,000	64,453,000	64,444,000	63,772,000	61,862,000	57,687,000	49,823,000	44,937,000	13,689,000	15,256,000	13,182,000	11,958,000	11,324,000	17,224,000	12,564,000	19,106,000	16,165,000	26,299,000	19,333,000	21,960,000	21,771,000	27,822,024	20,246,000	15,098,000	21,094,000	37,253,000	17,735,000	13,464,000	13,562,000	17,108,005	17,559,000	17,346,000	25,945,000	28,117,599	24,735,000	17,157,000	13,579,000	10,734,616	12,905,000	9,681,000	11,007,000	11,381,766	3,447,000	2,261,000	2,683,000	2,834,359	3,268,000	2,058,000	872,577
secured term loan		194,366,000	242,794,000	315,413,000	314,869,000	314,333,000	313,822,000	308,484,000	303,231,000			232,522,000	231,624,000	223,867,000	144,516,000	140,236,000	136,082,000	132,050,000	126,796,000	123,039,000	119,735,000
total liabilities	633,311,000	834,313,000	878,782,000	931,974,000	966,354,000	959,817,000																																																																												3,747,000	2,561,000	2,983,000
stockholders’ deficit:
preferred stock, 0.01 par value...
common stock, 0.01 par value...	2,131,000	2,105,000	2,099,000	2,092,000	2,085,000	2,071,000	2,066,000	2,063,000	2,058,000	1,898,000	1,895,000	1,889,000	1,879,000	1,864,000	1,859,000	1,856,000	1,843,000	1,798,000			1,769,000				1,541,000				1,101,000				984,000				738,000				734,000				720,000				591,000				509,000
additional paid-in capital	1,384,857,000	1,360,890,000	1,339,584,000	1,314,857,000	1,291,100,000	1,270,318,000	1,250,983,000	1,237,537,000	1,222,236,000	1,205,744,000	1,191,981,000	1,177,192,000	1,158,118,000	1,138,654,000	1,125,453,000	1,115,443,000	1,098,498,000	1,040,769,000	1,022,975,000	1,010,779,000	1,002,408,000	994,811,000	991,574,000	880,319,000	877,300,000	795,589,000	790,076,000	784,278,000	780,400,000	776,724,000	720,587,000	718,037,000	714,869,000	711,965,000	620,453,000	618,009,000	566,913,000	564,791,000	562,634,000	560,762,000	558,113,000	556,095,000	553,610,000	546,698,000	542,943,000	538,959,000	536,864,000	426,520,000	420,988,000	420,097,000	399,684,000	393,738,000	391,611,000	390,783,000	386,966,000	382,181,000	367,829,000	365,868,000	364,593,000	363,235,000	361,520,258	360,153,000	358,604,000	350,325,000	348,571,914	300,989,000	298,106,000	296,626,000	295,207,583	293,831,000	292,132,000	290,750,000	288,683,369	287,330,000	220,321,000	217,979,000	216,310,578	215,107,000	213,920,000	212,674,000	210,014,946	178,844,000	177,659,000	177,653,000	154,880,528	154,575,000	154,369,000	131,910,935
accumulated other comprehensive income	38,000	1,140,000	1,646,000	1,132,000	921,000	2,293,000	557,000	771,000	1,337,000	800,000	690,000	585,000	26,000	-98,000	15,000	186,000	177,000	114,000	87,000	182,000	3,000	9,000	3,000	14,000	39,000	60,000	41,000											22,000	46,000	48,000				10,000	-130,000	2,000	3,000	2,000	4,000	2,000	6,000	15,000	27,000	40,000	40,000	49,000	40,000	50,000	92,000	82,000	105,710	119,000	63,000	77,000	-25,783	40,000	40,000	68,000	103,507	133,000	252,000	726,000	378,057	152,000	-4,000	26,000	32,463	54,000	9,000
accumulated deficit	-1,506,179,000	-1,752,024,000	-1,764,923,000	-1,770,008,000	-1,770,040,000	-1,743,245,000	-1,729,212,000	-1,716,538,000	-1,681,159,000	-1,619,428,000	-1,583,279,000	-1,507,953,000	-1,454,620,000	-1,383,079,000	-1,340,559,000	-1,281,700,000	-1,207,504,000	-1,189,725,000	-1,130,924,000	-1,087,726,000	-1,023,442,000	-962,949,000	-916,834,000	-878,227,000	-840,628,000	-838,006,000	-800,414,000	-762,785,000	-731,969,000	-704,537,000	-674,940,000	-656,494,000	-631,843,000	-612,300,000	-597,166,000	-580,280,000	-566,061,000	-561,558,000	-550,030,000	-533,749,000	-510,917,000	-492,782,000	-478,161,000	-483,062,000	-467,898,000	-456,226,000	-447,495,000	-432,846,000	-422,709,000	-417,280,000	-409,279,000	-397,107,000	-392,601,000	-381,548,000	-371,848,000	-359,572,000	-353,520,000	-340,328,000	-325,870,000	-309,599,000	-296,572,332	-286,372,000	-275,508,000	-265,315,000	-262,719,149	-277,871,000	-267,244,000	-258,560,000	-249,267,614	-259,338,000	-250,343,000	-237,634,000	-224,536,044	-222,253,000	-211,269,000	-204,306,000	-195,480,520	-185,431,000	-169,828,000	-159,745,000	-151,862,667	-144,702,000	-137,057,000	-131,409,000	-125,763,899	-120,475,000	-115,179,000
total stockholders’ deficit	-119,153,000	-387,889,000	-421,594,000	-451,927,000	-475,934,000	-468,563,000	-475,606,000	-476,167,000	-455,528,000	-410,986,000	-388,713,000	-328,287,000	-294,597,000	-242,659,000	-213,232,000	-164,215,000	-106,986,000																															-5,723,000			-9,047,000	-2,840,000
total liabilities and stockholders’ deficit	514,158,000	446,424,000	457,188,000	480,047,000	490,420,000	491,254,000	472,419,000	467,892,000	516,960,000	522,924,000	529,885,000	509,737,000	550,000,000	558,594,000	510,538,000	527,720,000	588,151,000
current assets held for sale		29,173,000	29,170,000
non-current assets held for sale		4,058,000	2,825,000
current liabilities held for sale		26,423,000	23,708,000
non-current liabilities held for sale		436,000	454,000
investments						233,172,000	193,617,000	252,221,000	278,344,000	246,685,000	264,455,000	243,022,000	119,543,000	179,959,000	144,912,000	47,964,000	3,212,000		8,114,000	13,454,000	28,239,000	46,827,000	15,935,000	11,185,000	22,054,000	38,532,000	61,387,000	72,753,000	77,736,000	67,737,000	53,636,000	47,540,000	64,115,000	43,848,000	40,977,000	23,524,000	32,546,000	17,434,000	27,079,000	22,914,000	22,664,000	23,700,000	17,584,000	19,160,000	18,232,000	5,977,000	10,589,000	17,807,000	16,891,000	16,541,000	9,358,000	13,462,000	14,708,000	17,062,000	12,958,000	15,617,000	25,274,000
deferred revenue										522,000	1,779,000	1,200,000	1,224,000	1,554,000	1,521,000	1,471,000	1,421,000	602,000	551,000																																															2,509,000	2,528,000	2,547,000	2,565,285	4,345,000	4,345,000	4,756,000	4,658,266	4,680,000	4,620,000	3,161,000	2,699,463	2,699,000	2,391,000	2,162,000	873,786	300,000	300,000	300,000	300,000	300,000	300,000	300,000
lease financing obligation										2,282,000	2,530,000	2,491,000	2,369,000	2,196,000	2,134,000	2,081,000	1,819,000	1,452,000	981,000	1,001,000	1,179,000	925,000	1,096,000	1,301,000	1,377,000				47,000	66,000	78,000	76,000	75,000	73,000	2,704,000	2,704,000	2,704,000	2,675,000	2,589,000	2,506,000	2,375,000
secured term loans										297,995,000	293,176,000
stockholders’ equity:
interest payable																		25,553,000	25,217,000	23,547,000	21,670,000	19,304,000	17,806,000	16,381,000	14,904,000	13,423,000	14,745,000	13,392,000	11,848,000	10,427,000	14,832,000	13,465,000	12,095,000	10,705,000	11,587,000	10,291,000	8,990,000	7,563,000	9,203,000	7,974,000	6,746,000	5,517,000	4,450,000	7,241,000	6,029,000	4,824,000	3,786,000	4,552,000	3,867,000	2,734,000	3,658,000	3,068,000	1,998,000	928,000	3,500,000	2,450,000	1,400,000	350,000	1,318,000	257,000
non-recourse notes payable																		30,000,000	30,000,000	30,000,000	30,000,000	29,890,000	29,780,000	29,671,000	29,561,000	29,451,000	29,341,000	29,231,000	29,121,000	29,012,000	28,902,000	28,792,000	28,682,000	28,572,000	28,463,000	28,353,000	28,243,000	28,133,000	28,023,000	27,914,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000
inventories																		13,663,000	9,846,000	5,113,000		6,241,000	5,233,000																															263,000	263,000	263,000		898,000	898,000	898,000	898,076	898,000	907,000	844,000	6,281,263
liabilities and stockholders’ equity
royalty financing obligation																		142,114,000	136,862,000	131,296,000	124,717,000
preferred stock, 0.001 par value...
total stockholders’ equity																		-147,044,000	-106,075,000	-74,988,000		33,637,000	76,507,000	3,648,000	38,252,000		-9,193,000	22,507,000	49,235,000	72,873,000	46,184,000	62,054,000	83,767,000	100,632,000	24,076,000	38,530,000	1,578,000	3,993,000	13,387,000	27,798,000	47,724,000	64,045,000	76,089,000	64,371,000	75,635,000	83,454,000	90,089,000			3,410,000				9,784,000	15,659,000	23,150,000	14,806,000	26,042,000	39,266,000	54,169,000	65,503,226	74,349,000	83,608,000	85,527,000	86,266,050	23,545,000	31,285,000	38,517,000	46,426,227	35,008,000	42,423,000	54,223,000	64,905,054	65,609,000	9,343,000	13,993,000	21,155,009		44,393,000	53,220,000	58,440,414	34,406,000	40,864,000	46,506,000	29,334,212	34,317,000	39,407,000	40,127,811
total liabilities and stockholders’ equity																		265,763,000	277,284,000	284,431,000	334,715,000	176,226,000	214,706,000	136,589,000	175,282,000	90,500,000	116,344,000	142,338,000	146,841,000	168,308,000	136,644,000	155,372,000	178,259,000	191,492,000	113,509,000	129,513,000	89,847,000	91,502,000	82,217,000	102,881,000	124,555,000	138,956,000	150,181,000	129,867,000	136,874,000	137,125,000	141,975,000	43,387,000	48,866,000	53,205,000	39,916,000	46,899,000	57,439,000	64,094,000	76,236,000	80,085,000	82,208,000	92,511,000	108,412,000	122,766,000	109,447,235	111,354,000	116,103,000	124,655,000	142,190,106	60,588,000	64,694,000	72,602,000	84,691,677	99,351,000	107,649,000	129,144,000	142,716,839	141,154,000	78,426,000	67,916,000	68,485,421		91,879,000	102,224,000	99,248,394	38,153,000	43,425,000	49,489,000	32,468,571	37,885,000	41,765,000	41,300,388
common stock																			1,787,000	1,777,000		1,766,000	1,764,000	1,542,000		1,104,000	1,104,000	1,103,000		1,096,000	989,000	987,000		984,000	804,000	804,000		738,000	737,000	737,000		733,000	732,000	725,000		719,000	717,000	601,000		591,000	542,000	514,000		509,000	501,000	492,000		452,000	451,000	451,000		449,000	449,000	440,000			383,000	383,000		382,000	381,000	381,000		380,000	295,000	294,000
deferred collaboration revenue																				405,000	150,000	432,000	715,000	1,067,000	2,120,000	221,000	221,000	221,000	221,000	200,000	300,000	7,300,000	8,484,000	8,686,000	1,717,000	1,869,000	2,022,000	2,282,000	2,134,000	2,163,000	2,163,000	2,102,000	6,453,000	1,490,000	1,481,000	1,481,000	1,482,000	1,473,000	1,473,000	1,539,000	1,538,000	1,536,000	1,392,000	1,308,000	4,072,000	2,400,000	9,786,000	3,370,000	3,321,000	2,497,000	2,496,534	2,497,000	2,497,000	2,497,000	2,496,534
receivables																					8,646,000																									3,238,000	897,000	3,280,000	2,115,000	2,369,000	1,024,000	4,325,000	4,562,000
senior credit facility																						19,148,000	19,056,000	14,026,000	9,020,000	4,036,000			4,580,000	1,621,000	6,530,000	6,497,000	6,464,000	4,727,000	2,997,000	1,276,000	22,777,000	22,665,000
total stockholders’ (deficit) equity																					-19,262,000					-41,253,000																							-1,126,000				-454,000
receivables from collaborations																						5,422,000	3,997,000	5,642,000	22,146,000	3,598,000	3,602,000	5,002,000	4,293,000	3,394,000	2,342,000	5,694,000	6,117,000	8,985,000	3,325,000	9,564,000	8,768,000	5,968,000	2,234,000	7,384,000	6,243,000	7,495,000	4,296,000	5,594,000	3,849,000									3,768,000	5,084,000	5,852,000	5,831,000	11,634,000	15,961,000	26,062,000	30,227,210	25,564,000	20,531,000	26,627,000	33,722,207	11,626,000	8,075,000	9,847,000	11,982,430	13,102,000	14,850,000	28,579,000	39,127,676				4,556,145
deferred rent																													54,000	81,000	107,000	131,000	155,000	178,000	201,000	223,000	244,000	265,000	297,000	313,000	329,000	345,000	361,000	378,000														138,000	151,000	52,000	52,537	52,000	52,000	52,000	52,537	53,000	53,000	40,000	40,000	40,000	40,000	40,000
other non-current liabilities																										3,543,000	3,742,000	3,889,000
deferred collaboration expense																												9,000	9,000	8,000	12,000	152,000	210,000	218,000	79,000	82,000	85,000	98,000	89,000	90,000	90,000	88,000	101,000	76,000	76,000	76,000	75,000	75,000	75,000	73,000	73,000	418,000	412,000	404,000	519,000	452,000	2,301,000	753,000	751,000	719,000	718,719	719,000	719,000	374,000	374,221	374,000	376,000	376,000	376,972	10,719,000	10,951,000	11,182,000	11,407,120	11,640,000	11,872,000	11,470,000	10,597,750	10,787,000	7,824,000	7,900,000	5,825,243
accumulated other comprehensive loss																												-89,000	-297,000	-410,000	-452,000	-476,000	-243,000	-17,000	-15,000	-3,000	-12,000				-206,000	-1,000	-92,000
foreign currency derivative																																						1,904,000	974,000								2,805,000	981,000		1,581,000	1,678,000	2,791,000	4,749,000	5,531,000	4,959,000	3,962,000	4,000,000	2,926,000	2,340,000	1,342,000
receivables from product sales																																													5,641,000
deferred product sales revenue																																										16,000	46,000	5,533,000	5,605,000
furniture and equipment																																										1,146,000	1,047,000	727,000	207,000	210,000	216,000	260,000	306,000	359,000	425,000	486,000	583,000	751,000	882,000	999,000	1,098,000	1,353,000	1,537,000	1,734,000	1,929,049	3,087,000	3,330,000	3,564,000	3,871,653	4,175,000	4,429,000	4,566,000	4,880,475	5,271,000	5,232,000	5,086,000	5,294,079	4,120,000	3,169,000	3,062,000	3,029,271	2,679,000	2,671,000	2,760,000	2,407,954	2,342,000	2,456,000	2,634,000	2,817,154	2,948,000	3,163,000	4,557,287
3
interest reserve																																																							1,742,000	1,742,000	1,742,000	1,742,000	3,000,000	3,000,000
commitments and contingencies
common stock, .01 par value...																																																									457,000				449,590				439,068				382,751				379,672				292,488	292,000	292,000	291,000	288,135	264,000	262,000	262,000	217,583			176,571
marketable securities																																																										21,558,000	40,583,000	37,129,000	40,323,169	49,595,000	41,531,000	43,169,000	27,838,812	17,259,000	28,446,000	37,909,000	39,186,404	48,726,000	13,260,000	17,674,000	19,542,193	24,620,000	23,690,000	27,849,000	33,040,038	36,082,000	29,712,000
preferred stock: 5,000 shares authorized; none issued and outstanding
accrued vacation																																																												714,000	585,211	823,000	861,000	857,000	839,362	828,000	842,000	780,000	794,375	828,000	914,000	888,000	824,143	770,000	710,000	672,000	641,474	602,000	537,000	496,000	442,977				299,955			173,015
preferred stock: shares authorized — 5,000 series b junior participating preferred stock, .001 par value...
preferred stock: shares authorized — 5,000,000 series b junior participating preferred stock, .001 par value...
preferred stock: shares authorized – 5,000
series b junior participating preferred stock, .001 par value...
95,000; shares issued and outstanding – 38,735 in 2009 and 38,275 in 2008																																																																		387,000
preferred stock: shares authorized — 5,000
preferred stock: shares authorized – 5,000 series b junior participating preferred stock, .001 par value...
preferred stock: shares authorized - 5,000
patents and licenses, net of accumulated amortization of 32,094 in 2006
preferred stock: shares authorized - 5,000,000 series b junior participating preferred stock, .001 par value...
receivables from collaborations – billed																																																																										5,005,000
receivables from collaborations – unbilled																																																																										15,743,000
patents and licenses																																																																										297,000	314,000	303,000		260,000	248,000	222,000
receivables from collaborations — billed																																																																											3,460,000	3,871,000
receivables from collaborations — unbilled																																																																											14,813,000	4,496,000
patents and licenses, net of accumulated amortization of 32,094 in 2006 and 13,076 in 2005																																																																													290,694
receivable from collaboration																																																																														3,139,000	1,975,000	630,000	30,000,000
stockholders' equity:
series a convertible preferred stock, .01 par value...
total stockholders' equity																																																																														30,022,000
total liabilities and stockholders' equity																																																																														80,198,000
securities held-to-maturity																																																																																25,422,000	21,103,572	21,738,000	23,812,000	18,988,000	14,334,631	9,144,000	7,118,000	10,624,518
patents and licenses, net of accumulated amortization of 13,076 in 2005 and 3,934 in 2004																																																																																	187,635
preferred stock: shares authorized - 5,000,000
patents																																																																																		284,000	268,000	258,000		242,000	195,000
patents and licenses, less accumulated amortization of 3,934 in 2004 and 955 in 2003																																																																																					248,586
authorized - 1,800; shares issued and outstanding - none
authorized - 21.5; shares issued and outstanding - none
45,000; shares issued and outstanding -
21,682 in 2004 and 17,871 in 2003																																																																																							217,000
patents and licenses, less accumulated amortization of 201 in 2002 and 6,666 in 2001																																																																																								97,523
stockholders’ equity
preferred stock: shares authorized — 5,000,000

Cashflow Statements:

Quarterly

Annual

Unit: USD	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-09-30	2021-06-30	2021-03-31	2020-06-30	2020-03-31	2019-09-30	2019-06-30	2019-03-31	2018-09-30	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-09-30	2011-06-30	2011-03-31	2010-09-30	2010-06-30	2010-03-31	2009-09-30	2009-06-30	2009-03-31	2008-09-30	2008-06-30	2008-03-31	2007-09-30	2007-06-30	2007-03-31	2006-09-30	2006-06-30	2006-03-31	2005-09-30	2005-06-30	2005-03-31	2004-09-30	2004-06-30

cash flows from operating activities:
net income	245,845,000	12,899,000	5,085,000	32,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	394,000	335,000	329,000	331,000	309,000	311,000	320,000	306,000	423,000	420,000	407,000	405,000	396,000	389,000	335,000	317,000	606,000	377,000	178,000	401,000	218,000	539,000	357,000	176,000	572,000	377,000	186,000	522,000	344,000	172,000	311,000	136,000	47,000	137,000	94,000	45,000	137,000	97,000	53,000	247,000	183,000	97,000	461,000	325,000	168,000	630,000	445,000	225,000	1,097,000	789,000		1,217,000	823,000	410,000	1,163,000	756,000	372,000	752,000	475,000	231,000	593,000	424,000	205,000	657,000	441,000	224,000	726,000	487,000
inventory obsolescence	-71,000	30,000	817,000	209,000	-11,000	1,360,000			186,000	-2,000	2,000	236,000
stock-based compensation expense	23,793,000	18,601,000	21,304,000	21,368,000	21,339,000	17,249,000	13,173,000	13,652,000	16,488,000	12,279,000	12,841,000	14,007,000	15,282,000	9,951,000	9,867,000	9,601,000	26,140,000	13,111,000	5,479,000	6,034,000	2,754,000	14,031,000	8,702,000	3,317,000	7,072,000	4,987,000	2,903,000	10,307,000	4,788,000	2,462,000	6,478,000	4,491,000	2,645,000	7,773,000	5,934,000	2,259,000	6,550,000	5,129,000	1,610,000	3,479,000	2,521,000	1,602,000	3,345,000	2,178,000	1,044,000	3,872,000	2,728,000	1,467,000	4,994,000	3,566,000	1,406,000	4,179,000	2,794,000	1,328,000	4,509,000	2,976,000	1,593,000	4,371,000	2,810,000	1,376,000	2,238,000	1,177,000	420,000
equity modification associated with sale of biocryst ireland
mark-to-market adjustment on share-based liability
payment of pharmakon pik interest	-14,551,000	-3,661,000
non-cash interest expense on royalty financing obligations	13,324,000	12,923,000
non-cash interest expense on secured term loan and amortization of debt issuance costs	0	384,000
amortization of discount on investments	-1,091,000	-707,000	-1,150,000	-1,383,000
loss on extinguishment of debt	10,421,000	2,740,000							0	0
loss on impairment
gain on sale of non-financial asset	0
gain on sale of biocryst ireland
changes in operating assets and liabilities:
increase in receivables	-15,494,000	-17,000
increase in inventory	-515,000
decrease in prepaid expenses and other assets	-1,937,000	-5,918,000
decrease in royalty financing obligations	-13,188,000	-18,319,000
increase in accounts payable and accrued expenses	35,361,000
decrease in deferred revenue
net cash from operating activities	291,960,000	41,624,000	41,302,000	-27,517,000	-5,213,000	8,245,000	-1,368,000	-53,684,000	-8,918,000	-19,897,000	-18,814,000	-47,512,000	-23,849,000	-32,444,000	-27,757,000	-77,800,000	-109,698,000	-86,422,000	-61,011,000	-54,322,000	-23,281,000	-79,136,000	-51,499,000	-26,998,000	-68,580,000	-33,548,000	-19,653,000	-30,624,000	-18,194,000	-8,527,000	-47,584,000	-30,026,000	-18,842,000	1,712,000	14,372,000	-3,726,000	-24,661,000	-16,061,000	-8,959,000	-22,015,000	-14,093,000	-11,198,000	-30,367,000	-18,590,000	-12,248,000	-28,267,000	-17,798,000	-14,327,000	-22,735,000	-13,507,000	-5,188,000	-25,854,000	-20,728,000	-9,060,000	-16,336,000	-10,416,000	-4,501,000	-8,993,000	-4,252,000	-3,397,000	-335,000	12,676,000	26,347,000	-17,593,000	-11,452,000	-5,537,000	-12,735,000	-8,871,000
capital expenditures	-802,000	-1,344,000	-179,000	-143,000	-675,000	-59,000	-155,000	-235,000	-554,000	-987,000	-467,000	-160,000	0	-175,000	-244,000	-406,000	-1,277,000	-912,000	-99,000	-187,000	-116,000	-263,000	-180,000	-93,000	-262,000	-221,000	-35,000	-213,000	-24,000	-3,000	-5,278,000	-5,099,000	-3,260,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-179,000	-78,000	-41,000	-166,000	-142,000
free cash flows	291,158,000	40,280,000	41,123,000	-27,660,000	-5,888,000	8,186,000	-1,523,000	-53,919,000	-9,472,000	-20,884,000	-19,281,000	-47,672,000	-23,849,000	-32,619,000	-28,001,000	-78,206,000	-110,975,000	-87,334,000	-61,110,000	-54,509,000	-23,397,000	-79,399,000	-51,679,000	-27,091,000	-68,842,000	-33,769,000	-19,688,000	-30,837,000	-18,218,000	-8,530,000	-52,862,000	-35,125,000	-22,102,000	1,712,000	14,372,000	-3,726,000	-24,661,000	-16,061,000	-8,959,000	-22,015,000	-14,093,000	-11,198,000	-30,367,000	-18,590,000	-12,248,000	-28,267,000	-17,798,000	-14,327,000	-22,735,000	-13,507,000	-5,188,000	-25,854,000	-20,728,000	-9,060,000	-16,336,000	-10,416,000	-4,501,000	-8,993,000	-4,252,000	-3,397,000	-335,000	12,676,000	26,347,000	-17,772,000	-11,530,000	-5,578,000	-12,901,000	-9,013,000
cash flows from investing activities:
acquisitions of property and equipment	-802,000	-1,344,000	-179,000	-143,000	-675,000	-59,000	-155,000	-235,000	-554,000	-987,000	-467,000	-160,000		-175,000	-244,000	-406,000	-1,277,000	-912,000	-99,000	-187,000	-116,000	-263,000	-180,000	-93,000	-262,000	-221,000	-35,000	-213,000	-24,000	-3,000	-5,278,000	-5,099,000	-3,260,000
purchases of investments	-125,503,000	-58,634,000	-29,341,000	-48,762,000																-15,438,000		-3,018,000	-3,018,000	-3,018,000	-43,158,000	-16,754,000	-4,327,000	-39,572,000	-33,070,000					-48,343,000	-19,407,000	-3,378,000	-15,852,000	-12,651,000	-9,367,000	-15,232,000	-369,000		-14,487,000	-14,534,000	-3,666,000
sales and maturities of investments	49,000,000	73,000,000					110,000,000	117,000,000	129,069,000	147,995,000	66,325,000	41,688,000	77,741,000	35,655,000			28,201,000	20,089,000	14,771,000	21,417,000	10,840,000	64,954,000	41,357,000	18,992,000	51,355,000	34,435,000	20,289,000	32,527,000	23,873,000	14,136,000	38,272,000	19,064,000	6,320,000	35,874,000	24,884,000	2,482,000	29,000,000	20,900,000	8,350,000	13,845,000	6,820,000	2,380,000	35,515,000	25,811,000	15,605,000
sale of non-financial asset	0
proceeds from sale of biocryst ireland, net of cash divested
net cash from investing activities	-83,488,000	13,572,000	29,127,000	27,095,000	17,797,000	8,489,000	-2,449,000	28,756,000	-28,473,000	23,119,000	-19,035,000	-107,109,000	77,215,000	-69,543,000	-97,438,000	-38,472,000	26,924,000	19,177,000	14,673,000	5,792,000	10,724,000	61,673,000	38,159,000	15,881,000	7,935,000	17,460,000	15,927,000	-8,834,000	-13,032,000	12,881,000	33,100,000	11,151,000	2,707,000	-15,017,000	3,124,000	-3,948,000	13,108,000	8,243,000	-1,023,000	-1,205,000	4,604,000	2,072,000	21,238,000	9,563,000	11,540,000	14,010,000	-2,331,000	7,759,000	-7,902,000	-14,162,000	-16,409,000	20,132,000	12,092,000	2,933,000	492,000	3,927,000	746,000	-18,069,000	5,809,000	7,892,000	-23,947,000	-19,510,000	-14,731,000	-6,138,000	-10,956,000	-4,062,000	-6,753,000	-7,187,000
cash flows from financing activities:
net proceeds from common stock issued under stock-based compensation plans	657,000	2,647,000	3,421,000	2,390,000	-586,000	2,085,000	264,000	1,681,000	-178,000	1,487,000	1,954,000	5,077,000	4,199,000	3,253,000	147,000	7,356,000	12,250,000	7,474,000	2,900,000	798,000	266,000	1,161,000	977,000	563,000	1,495,000	736,000	268,000	1,491,000	1,068,000	950,000	204,000	33,000	7,000
withholding taxes paid on stock-based awards	-6,002,000	-628,000	-866,000	-1,351,000	-3,084,000	-261,000	-1,840,000	-2,350,000
common stock issued to directors in lieu of cash retainer	23,000	21,000	9,000	6,000	5,000	6,000
net proceeds from term loans
repayment of principal on term loans
prepayment premium and fees on term loans
payment of debt issuance costs on pharmakon tranche a term loan									0	-262,000
principal payments on royalty financing obligations	-6,477,000	-12,450,000
payment of royalty release fees
principal payments on finance lease liabilities	-424,000	-513,000	-536,000	-516,000	-356,000	-556,000	-402,000	-390,000
net cash from financing activities	-217,960,000	-58,814,000	-73,686,000	529,000	-4,021,000	1,274,000	-1,966,000	-1,048,000	-3,173,000	1,225,000	29,356,000	5,077,000	4,199,000	76,325,000	147,000	7,356,000	12,250,000	7,474,000	2,900,000	108,463,000	266,000	20,638,000	20,454,000	20,040,000	61,167,000	-2,751,000	-1,476,000	135,130,000	48,818,000	48,700,000	20,972,000	-1,363,000	138,000	5,392,000	4,745,000	1,501,000	111,546,000	108,173,000	2,402,000	28,379,000	8,365,000	3,040,000	16,644,000	14,507,000	11,925,000	23,076,000	23,515,000	24,288,000	686,000	565,000	348,000	1,606,000	104,000	90,000	641,000	475,000	475,000	66,736,000	1,203,000	294,000	2,858,000	2,732,000	2,242,000	23,990,000	22,810,000	22,810,000	21,356,000	21,163,000
effect of exchange rates on cash, cash equivalents and restricted cash	-72,000	-468,000	1,359,000	451,000
decrease in cash, cash equivalents and restricted cash					7,259,000	18,859,000	-5,926,000	-26,316,000		4,700,000	-8,810,000	-149,640,000		-25,676,000	-124,839,000	-108,876,000	-70,455,000		-43,438,000
cash, cash equivalents and restricted cash:
beginning of year
end of year
reconciliation of cash, cash equivalents and restricted cash:
cash and cash equivalents	5,658,000	-3,955,000	-17,157,000	105,190,000
restricted cash	-378,000	87,000	201,000	291,000
restricted cash in other assets	0	0	0	1,400,000
total cash, cash equivalents and restricted cash	5,280,000	-3,868,000	-16,956,000	106,881,000
supplemental cash flow disclosure:
cash paid for interest				9,153,000	10,141,000	10,201,000	5,054,000	4,987,000
taxes withheld on stock-based awards included in accrued expenses				276,000	513,000	56,000	-1,657,000	1,846,000
capitalized software costs included in accrued expenses
repayment of pharmakon term loan principal		-46,339,000
prepayment premium and fees on pharmakon term loan		-1,552,000
decrease in cash, cash equivalents and restricted cash, including cash classified within current assets held for sale		-4,086,000
less: cash and cash equivalents classified within current assets held for sale
net decrease in cash, and cash equivalents, and restricted cash		-3,868,000
beginning of period		0	0	106,323,000
end of period		-3,868,000	-16,956,000	106,881,000
decrease in inventory
decrease in accounts payable and accrued expenses
less: net increase in cash and cash equivalents classified within current assets held for sale
non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs				14,058,000	14,036,000	14,530,000	19,601,000	19,440,000	19,517,000	22,351,000	23,719,000	20,216,000	43,799,000	18,394,000	17,722,000	19,003,000
receivables				-13,987,000	-7,296,000	-3,317,000	-8,246,000	-3,839,000	-2,970,000	3,843,000	-8,987,000	2,019,000	-7,643,000	-1,484,000	-5,295,000	-7,048,000	-17,579,000	-18,976,000	-261,000	18,149,000	16,504,000	695,000	691,000	-709,000	2,723,000	3,775,000	423,000	-217,000	5,443,000	-796,000	275,000	4,009,000	-1,141,000	1,995,000	5,194,000	3,896,000	-1,123,000	1,218,000	-1,165,000	2,193,000	3,538,000	237,000
inventory				-870,000	-2,163,000	-1,520,000	739,000	-1,220,000	907,000	-3,386,000	898,000	131,000	-1,160,000	-3,674,000	-7,235,000	-354,000	-6,630,000	-2,809,000	1,927,000	-5,233,000		-127,000	649,000	1,049,000	-821,000	-221,000	-7,000	500,000	-805,000	-155,000	-620,000	-337,000	-337,000	683,000	-625,000	-527,000
prepaid expenses and other assets				-132,000	574,000	-1,466,000	1,745,000	1,106,000	710,000	-6,046,000	1,063,000	-2,547,000	-1,451,000	-82,000	1,270,000	-2,320,000	-3,460,000	-34,000	-9,850,000	817,000	-847,000	-1,018,000	84,000	321,000	-1,063,000	-347,000	-1,015,000	17,000	-87,000	-284,000	667,000	1,000,000	-313,000	1,331,000	769,000	1,848,000	-29,000	-408,000	892,000	-559,000	-53,000	-679,000
accounts payable and accrued expenses				-47,143,000	-2,446,000	-2,830,000	-12,534,000	-44,569,000	19,872,000	-9,264,000	-188,000	-27,226,000	5,279,000	-19,176,000	14,445,000	-22,908,000	16,692,000	2,743,000		-1,156,000	-5,100,000	9,975,000	2,579,000	-1,429,000	3,947,000	4,447,000	152,000	1,303,000	-975,000	1,642,000	-12,066,000	-8,742,000	-541,000	12,582,000	8,612,000	3,404,000	3,602,000	-247,000	-2,252,000	-4,925,000	-7,072,000	-7,114,000	-3,779,000	-2,575,000	-2,792,000	-9,712,000	-8,004,000	-6,309,000	-17,007,000	-22,155,000	-16,159,000	670,000	-3,620,000	-3,528,000	-10,286,000	-10,499,000	-2,311,000	12,020,000	4,502,000	2,383,000	-302,000	-3,218,000	-1,663,000
maturities of investments				76,000,000	58,000,000
increase in cash, cash equivalents and restricted cash				558,000														-59,686,000		59,933,000	-12,291,000	3,175,000	7,114,000	8,923,000	522,000	-18,839,000	-5,202,000
cash paid for taxes				1,000	378,000	360,000	679,000	186,000
net loss					-26,795,000	-14,033,000	-12,674,000	-35,379,000	-61,731,000	-36,149,000	-75,326,000	-53,333,000	-71,541,000	-42,520,000	-58,859,000	-74,196,000	-166,283,000	-107,482,000	-64,284,000	-76,206,000	-37,599,000	-106,275,000	-68,683,000	-31,054,000	-73,820,000	-44,223,000	-25,777,000	-46,239,000	-31,105,000	-14,219,000	-50,641,000	-39,113,000	-22,832,000	-24,884,000	-10,263,000	-15,164,000	-33,517,000	-24,786,000	-10,137,000	-24,679,000	-16,678,000	-4,506,000	-28,028,000	-18,328,000	-6,052,000	-43,756,000	-29,298,000	-13,027,000	-23,652,000	-12,788,000	-2,595,000	-28,603,000	-17,976,000	-9,292,000	-34,802,000	-25,807,000	-13,098,000	-26,772,000	-15,788,000	-8,825,000	-33,568,000	-17,965,000	-7,882,000	-18,938,000	-11,293,000	-5,645,000	-15,815,000	-10,519,000
adjustments to reconcile net loss to net cash from operating activities:
amortization of premium (discount) on investments
deferred revenue									-419,000	-1,346,000	570,000	-35,000	-438,000	143,000	111,000	75,000	457,000	403,000	255,000	-1,405,000	-1,053,000				-7,100,000	-7,000,000		-1,224,000	-897,000	-449,000	-1,075,000	-927,000	-480,000	1,602,000	5,820,000	-359,000																-1,929,000	-1,286,000	-643,000	-3,453,000	-2,367,000	-870,000	16,195,000	17,251,000	4,210,000	9,670,000	9,896,000	9,859,000
net proceeds from secured term loans									0
repayment of athyrium secured term loans principal									0	0
prepayment and repayment fees on athyrium secured term loans									0	0
amortization of premium/discount on investments						-2,039,000	-3,493,000	-3,181,000	-3,449,000	-2,597,000	-2,832,000	-1,385,000	-959,000	-730,000	-118,000	30,000	35,000	34,000	14,000	104,000	4,000	1,000	-17,000	-62,000	152,000	140,000	76,000	125,000	86,000	18,000	499,000	302,000
purchase of investments						-26,932,000	-112,294,000	-88,009,000		-123,889,000	-84,893,000	-148,637,000		-105,023,000	-101,194,000	-38,066,000
net proceeds from pharmakon tranche a term loan
effect of exchange rate on cash, cash equivalents, and restricted cash						851,000	-143,000	-340,000		253,000	-317,000	-96,000		-14,000	209,000	40,000
cash, cash equivalents and restricted cash at beginning of period						0	0	112,447,000		0	0	306,239,000		0	0	507,734,000	274,348,000	274,348,000	274,348,000	115,723,000	115,723,000	28,275,000	28,275,000	28,275,000	53,568,000	53,568,000	53,568,000
cash, cash equivalents and restricted cash at end of period						18,859,000	-5,926,000	86,131,000		4,700,000	-8,810,000	156,599,000		-25,676,000	-124,839,000	398,858,000	203,893,000	214,662,000	230,910,000	175,656,000	103,432,000	31,450,000	35,389,000	37,198,000	54,090,000	34,729,000	48,366,000
net proceeds from common stock issued to directors in lieu of cash retainer								11,000
interest payable																	3,884,000	3,547,000	1,877,000	2,902,000	1,477,000	1,575,000	2,897,000	1,544,000	-1,668,000	2,737,000	1,370,000	1,715,000	2,597,000	1,301,000	817,000	2,457,000	1,228,000	-512,000	-1,579,000	1,212,000	957,000	-81,000	685,000	736,000	1,660,000	1,070,000	-472,000	2,100,000	1,050,000	350,000	1,318,000	257,000
sale of common stock																				92,848,000					53,400,000			133,500,000	47,750,000	47,750,000				1,175,000	1,175,000	1,175,000	106,600,000	106,600,000		23,648,000	5,171,000	360,000	17,811,000	15,339,000	11,678,000
net proceeds from royalty financing liabilities
effects of exchange rates on cash, cash equivalents and restricted cash
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
inventory obsolescence expense
change in fair value of foreign currency derivative																				590,000	20,000	532,000	646,000	-406,000	606,000	1,185,000	1,804,000	1,858,000	1,943,000	1,543,000	7,372,000	6,441,000	2,753,000	793,000	332,000	-464,000	-732,000	3,350,000	1,526,000	-3,168,000	-3,071,000	-1,958,000	1,531,000	959,000	-38,000	2,926,000	2,340,000	1,342,000
acquisition of property and equipment
sale of pre-funded warrants																				14,817,000
proceeds from additional credit facility
payment of senior credit facility																									-4,025,000	-3,450,000	-1,725,000
net proceeds from secured term loan
net proceeds from royalty financing obligations
realized gain on investments																			1,000
non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs
proceeds from senior credit facility																						19,477,000	19,477,000	19,477,000	10,353,000						22,658,000
cash flows from operating activities
non-cash interest expense on royalty financing obligation																	24,125,000	15,604,000	7,536,000
non-cash paid in-kind interest on secured term loan																	12,871,000	7,459,000	3,549,000
amortization of debt issuance costs																	-556,000	-399,000	-58,000	681,000	341,000	936,000	596,000	255,000	676,000	455,000	232,000	658,000	439,000	220,000	335,000	220,000	110,000	329,000	220,000	110,000	329,000	220,000	110,000	329,000	220,000	110,000	329,000	220,000	110,000	246,000	137,000	31,000
cash flows from investing activities
cash flows from financing activities
effect of exchange rate on cash and cash equivalents																	69,000	85,000
operating activities
investing activities
financing activities
accounts payable, accrued expenses and other liabilities																			-7,373,000
operating activities:
loss on disposal of property and equipment																															21,000
net cash from operating activities:
investing activities:
net cash from investing activities:
financing activities:
net proceeds from royalty financing obligation
increase in lease financing obligation																									-56,000	-37,000	-19,000	139,000			300,000	214,000	131,000
net cash from financing activities:
net cash provided by financing activities
proceeds from sale of property and equipment
deferred collaboration expense																									144,000	140,000		51,000	35,000	18,000	43,000	37,000	19,000	-117,000	-136,000	14,000	45,000	30,000	15,000	5,120,000	5,106,000	95,000	2,200,000	1,984,000	1,950,000	1,155,000	977,000	830,000	335,000	155,000	93,000	284,000	188,000	95,000	688,000	456,000	225,000	-1,042,000	-1,274,000	-872,000	-4,962,000	-1,999,000	-2,075,000
decrease in lease financing obligation
depreciation, amortization, and impairment
change in restricted cash																												-1,576,000	-3,811,000	-1,252,000	106,000	-2,814,000	-353,000	-1,472,000	-1,419,000	-2,487,000	1,000	1,000	1,000	158,000	-1,821,000	-308,000	325,000	-1,605,000	-330,000		-791,000
increase in cash and cash equivalents																												95,672,000	17,592,000	53,054,000	6,488,000	-20,238,000		-7,913,000	22,241,000		99,993,000	100,355,000		5,159,000	-1,124,000	-6,086,000	7,515,000	5,480,000	11,217,000	8,819,000	3,386,000	17,720,000							-15,203,000	-6,014,000	-3,280,000	39,674,000	2,760,000	4,789,000	-21,424,000	-4,102,000	13,858,000	259,000	402,000	13,211,000	1,868,000	5,105,000
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
payment of foreign currency derivative collateral																															-2,190,000	-1,610,000											-2,010,000	-1,490,000	-410,000	-3,000,000	-2,450,000	-1,900,000
cash and cash equivalents at beginning of period																												22,104,000	22,104,000	22,104,000	28,899,000	28,899,000	28,899,000	54,540,000	54,540,000	54,540,000	21,164,000	21,164,000	21,164,000	20,891,000	20,891,000	20,891,000	16,444,000	16,444,000	16,444,000	13,622,000	13,622,000	13,622,000	41,125,000	41,125,000	41,125,000	22,342,000	22,342,000	22,342,000	31,155,000	31,155,000	31,155,000	4,418,000	4,418,000	4,418,000	29,157,000	29,157,000	29,157,000	8,838,000	8,838,000	8,838,000	11,941,000	11,941,000
cash and cash equivalents at end of period																												117,776,000	39,696,000	75,158,000	35,387,000	8,661,000	12,902,000	46,627,000	76,781,000	48,367,000	121,157,000	121,519,000	13,584,000	26,050,000	19,767,000	14,805,000	23,959,000	21,924,000	27,661,000	22,441,000	17,008,000	31,342,000	11,174,000	14,021,000	19,876,000	18,226,000	13,810,000	16,305,000	15,952,000	25,141,000	27,875,000	44,092,000	7,178,000	9,207,000	7,733,000	25,055,000	43,015,000	9,097,000	9,240,000	22,049,000	13,809,000	17,046,000
net cash provided (used) in investing activities:
decrease in cash and cash equivalents																																	-15,997,000			-6,173,000			-7,580,000										-29,951,000	-27,104,000	-21,249,000	-4,116,000	-8,532,000	-6,037,000
exercise of stock options																																		3,861,000	3,399,000	155,000	4,636,000	4,145,000	3,804,000	1,317,000	346,000	102,000	522,000	510,000	509,000	240,000	238,000	140,000	492,000	480,000	177,000	1,412,000	13,000		375,000	331,000	331,000	1,348,000	1,074,000	165,000	2,667,000	2,632,000	2,142,000	1,168,000	41,000	41,000
employee stock purchase plan sales																																		356,000	171,000	171,000	310,000	128,000	128,000	124,000	68,000	68,000	321,000	148,000	148,000	300,000	170,000	170,000	282,000	173,000	173,000	194,000	91,000	90,000	266,000	144,000	144,000	270,000	129,000	129,000	191,000	100,000	100,000	137,000	65,000	65,000
receipt of foreign currency derivative collateral
acquisitions of furniture and equipment																																		-1,076,000	-934,000	-565,000	-41,000	-7,000	-7,000	-26,000	-26,000		-115,000	-109,000	-69,000	-54,000	-53,000	-30,000	-312,000	-247,000	-83,000	-511,000	-371,000	-95,000	-1,140,000	-694,000	-164,000	-1,834,000	-609,000	-261,000	-859,000	-684,000	-556,000
loss on disposal of furniture and equipment
acquisition of furniture and equipment
proceeds from sale of furniture and equipment																																								50,000
receipt (payment) of foreign currency derivative collateral																																								3,290,000	2,780,000	2,510,000
gain on disposal of furniture and equipment																																								-47,000
deferred collaboration revenue																																					-880,000	-583,000	-296,000	-741,000	-447,000	-152,000	-9,366,000	-6,305,000	-7,681,000	-999,000	-425,000	-624,000	-1,873,000	-1,248,000	-624,000
(payment) receipt of foreign currency derivative collateral																																						-2,700,000	-1,530,000
receivables from collaborations																																											2,063,000	747,000	-22,000	18,593,000	14,266,000	4,165,000	8,158,000	13,191,000	7,095,000	356,000	3,907,000	2,135,000	26,026,000	24,278,000	10,549,000	-16,192,000	-13,717,000	-3,811,000
proceeds from sale furniture and equipment
purchases of treasury stock																																														-61,000	-61,000	-61,000	-4,000	-4,000	-2,000
issuance of non-recourse notes payable																																														30,000,000	30,000,000	30,000,000
interest reserve																																											1,742,000			-1,742,000	-3,000,000	-3,000,000
prepaid expenses and other current assets																																											-393,000	105,000	15,000	210,000	745,000	329,000	-131,000	-365,000	-219,000	-2,064,000	-5,607,000	445,000	-451,000	-489,000	-1,251,000	1,675,000	1,489,000	1,911,000	-865,000	-3,664,000	-1,887,000
inventories																																																	5,383,000	5,374,000	5,437,000
deferred rent																																														-40,000	-27,000	-13,000	-39,000	-26,000	-13,000	36,000	49,000	-10,000	270,000	280,000	290,000
purchases of marketable securities																																														-36,768,000	-27,676,000	-4,491,000	-50,094,000	-29,476,000	-18,123,000	-18,466,000	-500,000		-84,309,000	-28,668,000	-16,611,000	-49,236,000	-13,584,000		-42,101,000	-29,958,000	-17,639,000	-16,050,000	-15,987,000	-5,812,000	-15,223,000	-15,223,000
sales and maturities of marketable securities																																														50,832,000	26,189,000	12,280,000	42,504,000	15,561,000	1,797,000	39,109,000	12,963,000	3,028,000
common stock issuance costs																																														-94,000	-73,000		-84,000	-84,000
debt issuance costs																																														-4,309,000	-4,309,000	-4,061,000
sale of common stock, net of issuance costs																																																										65,118,000						22,685,000	22,704,000	22,704,000
depreciation, amortization and impairment																																																			391,000
purchases of patents and licenses																																																										-16,000	-30,000	-16,000	-78,000	-64,000	-36,000	-38,000	-21,000	-9,000	-63,000	-16,000
maturities of marketable securities																																																							85,941,000	33,289,000	17,521,000	33,017,000	20,032,000	8,169,000	19,091,000	11,196,000	3,500,000	10,129,000	5,130,000	1,800,000	8,699,000	8,194,000
cash and equivalents at beginning of year
depreciation and amortization of furniture and equipment
impairment of furniture and equipment
amortization of patents and licenses
impairment of patents and licenses
accounts payable
accrued expenses
accrued vacation
receivable from collaboration																																																													26,861,000	28,025,000	29,370,000
adjustments to reconcile net loss to net cash used in operating activities:
non-monetary compensation																																																																20,000	13,000	7,000	329,000	316,000
changes in operating assets and liabilities																																																																668,000	-613,000	-123,000	2,025,000	845,000
purchases of furniture and equipment																																																																-179,000	-78,000	-41,000	-166,000	-142,000
non-monetary compensation cost
employee stock purchase plan stock sales
proceeds from sale of common stock																																																																			21,356,000	21,163,000
deferred expense
purchase of marketable securities
principal payments of debt and capital lease obligations

BioCryst Pharmaceuticals, Inc(NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc
(NASDAQ:BCRX)